Filtered By:
Condition: Diabetes Type 2

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 3594 results found since Jan 2013.

Neuroprotective Mechanisms of Glucagon ‐like Peptide‐1‐based Therapies in Ischaemic Stroke: A Systematic Review based on Pre‐Clinical Studies
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - February 1, 2018 Category: Drugs & Pharmacology Authors: Ida R. Marlet, Joakim N.E. Ölmestig, Tina Vilsbøll, Jørgen Rungby, Christina Kruuse Tags: Mini ‐Review Source Type: research

Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease.
Authors: Román GC, Jackson RE, Gadhia R, Román AN, Reis J Abstract The mechanisms of action of the dietary components of the Mediterranean diet are reviewed in prevention of cardiovascular disease, stroke, age-associated cognitive decline and Alzheimer disease. A companion article provides a comprehensive review of extra-virgin olive oil. The benefits of consumption of long-chain ω-3 fatty acids are described. Fresh fish provides eicosapentaenoic acid while α-linolenic acid is found in canola and soybean oils, purslane and nuts. These ω-3 fatty acids interact metabolically with ω-6 fatty acids mainly linoleic...
Source: Revue Neurologique - September 16, 2019 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research

Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis
Conclusions: In summary, this meta-analysis indicated that the use of SGLT2 inhibitors did not decrease the risk of stroke. And for some T2DM patients with high-risk factor of stroke, SGLT2 inhibitors therapy may be more suitable compared to some oGLD such as dipeptidyl peptidase-4 inhibitors. The results of this meta-analysis are necessary to be confirmed with further studies and clinical trials.Cerebrovasc Dis
Source: Cerebrovascular Diseases - January 31, 2022 Category: Neurology Source Type: research

Association between Preexisting Sarcopenia and Stroke in Patients with Type 2 Diabetes Mellitus
ConclusionPreexisting sarcopenia increased the risk of stroke in patients with type 2 diabetes mellitus.
Source: The Journal of Nutrition, Health and Aging - September 14, 2022 Category: Nutrition Source Type: research

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
ConclusionGLP-1RA significantly reduces the risk of ischemic stroke in type 2 diabetics with cardiovascular risk factors.
Source: Frontiers in Endocrinology - December 5, 2022 Category: Endocrinology Source Type: research

Review: Intensive blood pressure control reduces stroke, but not mortality or MI, in type 2 diabetes.
CONCLUSION Intensive blood pressure control reduced stroke, but not myocardial infarction or mortality, compared with standard control in adults with type 2 diabetes.Intensive vs standard blood pressure (BP) targets in adults with type 2 diabetes*OutcomesNumber of trials (n)†Weighted event ratesMean follow-up 2 to 5 yIntensive BP targetStandard BP targetRRR (95% CI)NNT (CI)Mortality5 (6812)5.1%6.4%20% (-14 to 44)Not significantMyocardial infarction4 (6683)8.9%9.6%7% (-9 to 21)Not significantStroke4 (6683)1.9%3.1%39% (17 to 55)82 (58 to 188)*Abbreviations defined in Glossary. Weighted intensive BP target event rate, RRR, ...
Source: Annals of Internal Medicine - January 15, 2013 Category: Internal Medicine Authors: Moist L Tags: Ann Intern Med Source Type: research

Targets of Vascular Protection in Acute Ischemic Stroke Differ in Type 2 Diabetes.
The objective of the current study was to determine the effects of acute manipulation of potential targets for vascular protection (i.e., NFkB, peroxynitrite, and matrix metalloproteinases) on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of peroxynitrite decomposition catalyst FeTPPs,a non-specific NFkB inhibitor curcumin, or a broad-spectrum matrix metalloproteinase (MMP) inhibitor minocycline at reperfusion. Post-stroke infarct volume, edem...
Source: American Journal of Physiology. Heart and Circulatory Physiology - January 18, 2013 Category: Physiology Authors: Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Hafez S, Coucha M, Johnson MH, Ogbi SN, Fagan SC, Ergul A Tags: Am J Physiol Heart Circ Physiol Source Type: research

Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans.
Abstract Cerebral edema and hemorrhagic conversion are common, potentially devastating complications of ischemic stroke and are associated with high rates of mortality and poor functional outcomes. Recent work exploring the molecular pathophysiology of the neurogliovascular unit in ischemic stroke suggests that deranged cellular ion homeostasis due to altered function and regulation of ion pumps, channels, and secondary active transporters plays an integral role in the development of cytotoxic and vasogenic edema and hemorrhagic conversion. Among these proteins involved in ion homeostasis, the ischemia-induced, no...
Source: Neurosurgical Focus - January 1, 2014 Category: Neurosurgery Authors: Khanna A, Walcott BP, Kahle KT, Simard JM Tags: Neurosurg Focus Source Type: research

Case–control study of oral glucose‐lowering drugs in combination with long‐acting insulin and the risks of incident myocardial infarction and incident stroke
ConclusionsSulfonylureas in combination with long‐acting insulin may increase the risk of MI compared with the use of insulin alone. Metformin may be an important cardiovascular disease prevention therapy for patients on insulin therapy. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - November 8, 2015 Category: Drugs & Pharmacology Authors: James S. Floyd, Kerri L. Wiggins, Mark Christiansen, Sascha Dublin, William T. Longstreth, Nicholas L. Smith, Barbara McKnight, Susan R. Heckbert, Noel S. Weiss, Bruce M. Psaty Tags: Original Report Source Type: research

Gliptins‐mediated neuroprotection against stroke requires chronic pre‐treatment and is glucagon‐like peptide‐1 receptor independent
Abstract Gliptins are anti‐type 2 diabetic (T2D) drugs regulating glycaemia by preventing endogenous glucagon‐like peptide‐1 (GLP‐1) degradation. Chronically administered gliptins before experimental stroke can also induce neuroprotection and this effect is potentially relevant to reduce brain damage in high stroke‐risk T2D patients. However, it is unknown: 1) whether acute gliptins‐treatment after stroke (mimicking a post‐hospitalization treatment) is neuroprotective 2) whether gliptins‐mediated neuroprotection occurs via GLP‐1‐receptor (GLP‐1R) activation. To answer these two questions, wt and glp...
Source: Diabetes, Obesity and Metabolism - February 1, 2016 Category: Endocrinology Authors: Vladimer Darsalia, Martin Larsson, Grazyna Lietzau, David Nathanson, Thomas Nyström, Thomas Klein, Cesare Patrone Tags: LETTER TO THE EDITOR Source Type: research

Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - February 17, 2016 Category: Neurology Source Type: news

Is It Possible to Treat "Stroke-Like Symptoms" with Hemodialysis? (P4.390)
CONCLUSIONS • Diabetic patients with ESRD on HD can present with stroke-like symptoms associated with bilateral basal ganglia hypoattenuation . This presentation can be confused initially with a stroke. • Brain imaging can assist with making the diagnosis. The clinical presentation in our cases included slurred speech, ataxia, and bilateral lower extremity weakness. • Hemodialysis leaded to clinical improvement.Disclosure: Dr. Rodriguez Alvarez has nothing to disclose. Dr. Pillai has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Avagyan has nothing to disclose. Dr. Gold has nothing to disclose....
Source: Neurology - April 3, 2016 Category: Neurology Authors: Rodriguez Alvarez, M., Pillai, A., Gomez, E., Avagyan, A., Gold, M., Sternman, D., Thompson, L. Tags: General Neurology: Vascular Disease and Imaging Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Pre-stroke glycemia in patients with diabetes
Conclusion Insulin treatment and hyperlipidemia are associated with higher HbA1c levels in acute stroke patients with T2D. Poor adherence to diabetes treatment is associated with higher HbA1c levels only among patients with HbA1c ≥8%.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - July 4, 2017 Category: Endocrinology Source Type: research

Glucagon-like peptide-1 agonists and protection against stroke: A systematic review and meta-analysis
Aim: Type 2 diabetes is associated with an increased risk of stroke and a worse outcome following stroke. Among glucose-lowering modalities only pioglitazone (a thiazolinedione) has been shown to protect against stroke. Nonetheless, evidence from experimental with novel antidiabetic agents, such as glucagon-like peptide-1 (GLP-1) agonists, suggests potential neuroprotective effects, especially if treatment starts before stroke. Thus, we aimed to meta-analyze available evidence regarding the risk of stroke in individuals receiving GLP-1 agonists.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Fotios Barkas, Moses Elisaf, Haralampos Milionis Source Type: research